Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: F2RL1

Gene summary for F2RL1

Gene summary.

Gene information	Species	Human
	Gene symbol	F2RL1
	Gene ID	2150
	Gene name	F2R like trypsin receptor 1
	Gene Alias	GPR11
	Cytomap	5q13.3
	Gene Type	protein-coding
	GO ID	GO:0000165
	UniProtAcc	P55085

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
2150	F2RL1	P80T-E	Human	Esophagus	ESCC	8.47e-27	1.22e+00	0.155
2150	F2RL1	P83T-E	Human	Esophagus	ESCC	9.66e-09	1.17e-01	0.1738
2150	F2RL1	P91T-E	Human	Esophagus	ESCC	7.69e-07	3.74e-01	0.1828
2150	F2RL1	P107T-E	Human	Esophagus	ESCC	1.33e-27	1.10e+00	0.171
2150	F2RL1	P127T-E	Human	Esophagus	ESCC	1.70e-11	1.15e-01	0.0826
2150	F2RL1	P128T-E	Human	Esophagus	ESCC	5.26e-04	2.04e-01	0.1241
2150	F2RL1	P130T-E	Human	Esophagus	ESCC	1.46e-29	1.25e+00	0.1676
2150	F2RL1	C04	Human	Oral cavity	OSCC	7.39e-25	6.79e-01	0.2633
2150	F2RL1	C21	Human	Oral cavity	OSCC	3.11e-21	4.67e-01	0.2678
2150	F2RL1	C30	Human	Oral cavity	OSCC	3.14e-40	1.35e+00	0.3055
2150	F2RL1	C38	Human	Oral cavity	OSCC	2.38e-04	4.58e-01	0.172
2150	F2RL1	C51	Human	Oral cavity	OSCC	5.33e-08	4.09e-01	0.2674
2150	F2RL1	C57	Human	Oral cavity	OSCC	9.78e-08	2.25e-01	0.1679
2150	F2RL1	C06	Human	Oral cavity	OSCC	2.90e-05	5.79e-01	0.2699
2150	F2RL1	C08	Human	Oral cavity	OSCC	4.58e-50	1.16e+00	0.1919
2150	F2RL1	C09	Human	Oral cavity	OSCC	2.70e-03	1.41e-01	0.1431
2150	F2RL1	SYSMH1	Human	Oral cavity	OSCC	4.57e-03	1.75e-01	0.1127
2150	F2RL1	SYSMH2	Human	Oral cavity	OSCC	1.29e-07	2.47e-01	0.2326
2150	F2RL1	SYSMH3	Human	Oral cavity	OSCC	8.06e-15	3.47e-01	0.2442
2150	F2RL1	P5_S10_cSCC	Human	Skin	cSCC	3.31e-02	1.84e-02	-0.299

Page: 1 2 3 4 5

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0022411111	Esophagus	ESCC	cellular component disassembly	305/8552	443/18723	1.94e-23	4.57e-21	305
GO:1904951111	Esophagus	ESCC	positive regulation of establishment of protein localization	216/8552	319/18723	1.01e-15	6.86e-14	216
GO:0051222111	Esophagus	ESCC	positive regulation of protein transport	204/8552	303/18723	1.56e-14	8.38e-13	204
GO:000961518	Esophagus	ESCC	response to virus	238/8552	367/18723	6.65e-14	3.32e-12	238
GO:004312318	Esophagus	ESCC	positive regulation of I-kappaB kinase/NF-kappaB signaling	132/8552	186/18723	2.07e-12	8.58e-11	132
GO:0043122110	Esophagus	ESCC	regulation of I-kappaB kinase/NF-kappaB signaling	167/8552	249/18723	6.11e-12	2.32e-10	167
GO:000724919	Esophagus	ESCC	I-kappaB kinase/NF-kappaB signaling	183/8552	281/18723	3.02e-11	1.01e-09	183
GO:003298416	Esophagus	ESCC	protein-containing complex disassembly	151/8552	224/18723	3.45e-11	1.15e-09	151
GO:1902905111	Esophagus	ESCC	positive regulation of supramolecular fiber organization	142/8552	209/18723	5.51e-11	1.76e-09	142
GO:1902903111	Esophagus	ESCC	regulation of supramolecular fiber organization	237/8552	383/18723	9.06e-11	2.75e-09	237
GO:0044403111	Esophagus	ESCC	biological process involved in symbiotic interaction	186/8552	290/18723	1.43e-10	4.16e-09	186
GO:00516075	Esophagus	ESCC	defense response to virus	171/8552	265/18723	3.91e-10	1.05e-08	171
GO:01405465	Esophagus	ESCC	defense response to symbiont	171/8552	265/18723	3.91e-10	1.05e-08	171
GO:0030099111	Esophagus	ESCC	myeloid cell differentiation	232/8552	381/18723	1.22e-09	2.90e-08	232
GO:005149520	Esophagus	ESCC	positive regulation of cytoskeleton organization	147/8552	226/18723	2.93e-09	6.38e-08	147
GO:000701527	Esophagus	ESCC	actin filament organization	259/8552	442/18723	2.37e-08	4.50e-07	259
GO:003253520	Esophagus	ESCC	regulation of cellular component size	227/8552	383/18723	4.77e-08	8.60e-07	227
GO:003010018	Esophagus	ESCC	regulation of endocytosis	135/8552	211/18723	5.75e-08	1.02e-06	135
GO:003109818	Esophagus	ESCC	stress-activated protein kinase signaling cascade	154/8552	247/18723	8.53e-08	1.44e-06	154
GO:000726510	Esophagus	ESCC	Ras protein signal transduction	201/8552	337/18723	1.44e-07	2.30e-06	201

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35

Enriched KEGG pathways.

Pathway ID

Tissue

Disease Stage

Description

Gene Ratio

Bg Ratio

pvalue

p.adjust

qvalue

Count

Page: 1

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand	Receptor	LRpair	Pathway	Tissue	Disease Stage
GZMA	F2RL1	GZMA_F2RL1	PARs	Endometrium	Healthy
CTSG	F2RL1	CTSG_F2RL1	PARs	GC	Healthy
PRSS2	F2RL1	PRSS2_F2RL1	PARs	GC	Healthy
GZMA	F2RL1	GZMA_F2RL1	PARs	GC	Precancer
GZMA	F2RL1	GZMA_F2RL1	PARs	Prostate	BPH
GZMA	F2RL1	GZMA_F2RL1	PARs	Prostate	Healthy
PRSS3	F2RL1	PRSS3_F2RL1	PARs	Skin	ADJ
CTSG	F2RL1	CTSG_F2RL1	PARs	Skin	ADJ
GZMA	F2RL1	GZMA_F2RL1	PARs	Skin	ADJ
CTSG	F2RL1	CTSG_F2RL1	PARs	Skin	AK
GZMA	F2RL1	GZMA_F2RL1	PARs	Skin	AK
CTSG	F2RL1	CTSG_F2RL1	PARs	Skin	Healthy
GZMA	F2RL1	GZMA_F2RL1	PARs	Skin	Healthy
GZMA	F2RL1	GZMA_F2RL1	PARs	THCA	Cancer

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

F2RL1

SNV

Missense_Mutation

rs185549069

c.308N>A

p.Arg103Gln

p.R103Q

P55085

protein_coding

deleterious(0.04)

benign(0.103)

TCGA-AN-A046-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

F2RL1

SNV

Missense_Mutation

novel

c.946A>T

p.Ser316Cys

p.S316C

P55085

protein_coding

tolerated(0.05)

possibly_damaging(0.882)

TCGA-BH-A0AY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

F2RL1

insertion

Nonsense_Mutation

novel

c.703_704insCACATAAGTTAGCATAACATGCTAA

p.Leu235SerfsTer6

p.L235Sfs*6

P55085

protein_coding

TCGA-AN-A0FF-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

F2RL1

insertion

Frame_Shift_Ins

novel

c.947_948insAAATATTGATCTCTACATCCCCCAACACTCCA

p.Ser316ArgfsTer24

p.S316Rfs*24

P55085

protein_coding

TCGA-BH-A0AY-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

F2RL1

SNV

Missense_Mutation

novel

c.1076T>C

p.Leu359Pro

p.L359P

P55085

protein_coding

deleterious(0)

probably_damaging(0.956)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

F2RL1

SNV

Missense_Mutation

novel

c.998N>G

p.Ser333Cys

p.S333C

P55085

protein_coding

deleterious(0.03)

probably_damaging(0.967)

TCGA-C5-A8YQ-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Chemotherapy

cisplatin

F2RL1

SNV

Missense_Mutation

novel

c.945N>C

p.Lys315Asn

p.K315N

P55085

protein_coding

tolerated(0.26)

probably_damaging(0.913)

TCGA-EA-A97N-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

F2RL1

SNV

Missense_Mutation

novel

c.1018N>A

p.Asp340Asn

p.D340N

P55085

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-EI-6917-01

Colorectum

rectum adenocarcinoma

Male

<65

III/IV

Chemotherapy

5fluorouracil+oxaciplatina+l-folinian

F2RL1

SNV

Missense_Mutation

novel

c.1019N>G

p.Asp340Gly

p.D340G

P55085

protein_coding

deleterious(0)

probably_damaging(0.999)

TCGA-AJ-A23O-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

F2RL1

SNV

Missense_Mutation

c.376N>G

p.Ile126Val

p.I126V

P55085

protein_coding

tolerated(0.34)

benign(0.012)

TCGA-AP-A054-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Chemotherapy

carboplatin

Page: 1 2 3 4

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
2150	F2RL1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME		ERYTHROMYCIN	ERYTHROMYCIN	18212111
2150	F2RL1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME		AC-55541	CHEMBL493076	18720984
2150	F2RL1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME	agonist	178100874
2150	F2RL1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME		ROXITHROMYCIN	ROXITHROMYCIN	18212111
2150	F2RL1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME	antagonist	381744949
2150	F2RL1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME	agonist	178103272
2150	F2RL1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME	antagonist	178103271
2150	F2RL1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME	agonist	178100746
2150	F2RL1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME	agonist	178103269
2150	F2RL1	DRUGGABLE GENOME, G PROTEIN COUPLED RECEPTOR, KINASE, ENZYME	antagonist	178103270

Page: 1 2 3